Baxter International Inc. $BAX Shares Bought by Jeppson Wealth Management LLC

Jeppson Wealth Management LLC lifted its stake in Baxter International Inc. (NYSE:BAX) by 39.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,392 shares of the medical instruments supplier’s stock after buying an additional 2,395 shares during the period. Jeppson Wealth Management LLC’s holdings in Baxter International were worth $254,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Zions Bancorporation National Association UT purchased a new position in Baxter International in the 1st quarter worth approximately $27,000. Rossby Financial LCC purchased a new position in shares of Baxter International in the first quarter valued at $29,000. MassMutual Private Wealth & Trust FSB grew its holdings in Baxter International by 48.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 2,021 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 656 shares in the last quarter. Archer Investment Corp increased its stake in Baxter International by 20.5% during the 1st quarter. Archer Investment Corp now owns 2,935 shares of the medical instruments supplier’s stock worth $100,000 after buying an additional 500 shares during the period. Finally, Bruce G. Allen Investments LLC lifted its holdings in Baxter International by 35.2% in the 1st quarter. Bruce G. Allen Investments LLC now owns 3,546 shares of the medical instruments supplier’s stock worth $121,000 after buying an additional 924 shares in the last quarter. 90.19% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Morgan Stanley dropped their target price on Baxter International from $28.00 to $27.00 and set an “underweight” rating on the stock in a research report on Tuesday, July 15th. Barclays dropped their price objective on Baxter International from $41.00 to $36.00 and set an “overweight” rating on the stock in a report on Monday, August 4th. The Goldman Sachs Group cut Baxter International from a “buy” rating to a “neutral” rating and set a $25.00 target price for the company. in a research note on Friday, August 1st. Stifel Nicolaus restated a “hold” rating and issued a $25.00 price target (down previously from $36.00) on shares of Baxter International in a research note on Monday, August 4th. Finally, Evercore ISI reduced their price objective on shares of Baxter International from $44.00 to $42.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Three investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Baxter International presently has an average rating of “Hold” and an average price target of $30.11.

Baxter International Stock Performance

Shares of BAX opened at $22.55 on Thursday. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.30 and a quick ratio of 1.49. Baxter International Inc. has a 12-month low of $21.33 and a 12-month high of $39.57. The business’s fifty day moving average price is $24.64 and its 200 day moving average price is $28.73. The stock has a market capitalization of $11.58 billion, a PE ratio of -75.15, a price-to-earnings-growth ratio of 0.74 and a beta of 0.61.

Baxter International (NYSE:BAX) last posted its quarterly earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.01). Baxter International had a positive return on equity of 16.96% and a negative net margin of 1.42%.The business had revenue of $2.81 billion during the quarter, compared to the consensus estimate of $2.82 billion. During the same quarter in the previous year, the business posted $0.68 earnings per share. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. Equities research analysts forecast that Baxter International Inc. will post 2.48 EPS for the current year.

Baxter International Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 1st. Stockholders of record on Friday, August 29th will be issued a dividend of $0.17 per share. The ex-dividend date of this dividend is Friday, August 29th. This represents a $0.68 annualized dividend and a dividend yield of 3.0%. Baxter International’s dividend payout ratio is -226.67%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.